^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
Debio 0123
i
Other names: Debio 0123, Debio-0123, Debio0123
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Almac Discovery, Debiopharm
Drug class:
WEE1 inhibitor
Related drugs:
3d
A Study to Evaluate Safety and Preliminary Anti-tumor Activity of Debio 0123 as Monotherapy in Adult Participants With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=155, Active, not recruiting, Debiopharm International SA | Trial primary completion date: Jan 2026 --> Apr 2026
Trial primary completion date
|
CCNE1 (Cyclin E1)
|
Debio 0123
11d
MYTHIC: Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=464, Recruiting, Debiopharm International SA | Trial completion date: Dec 2026 --> Jun 2028 | Trial primary completion date: Jun 2026 --> Dec 2027
Trial completion date • Trial primary completion date
|
CCNE1 (Cyclin E1) • FBXW7 (F-Box And WD Repeat Domain Containing 7) • MUC16 (Mucin 16, Cell Surface Associated) • PPP2R1A (Protein Phosphatase 2 Scaffold Subunit Aalpha)
|
lunresertib (RP-6306) • Debio 0123 • camonsertib (RP-3500)
2ms
WIN-B: Clinical Study to Evaluate Debio0123 + Sacituzumab Govitecan Combination in TNBC or HR+/HER2- Advanced Breast Cancer (clinicaltrials.gov)
P1/2, N=76, Active, not recruiting, MedSIR | Recruiting --> Active, not recruiting
Enrollment closed
|
Trodelvy (sacituzumab govitecan-hziy) • Debio 0123
2ms
Debio 0123-101: Study of Oral Debio 0123 in Combination With Carboplatin in Participants With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=76, Terminated, Debiopharm International SA | Trial completion date: Nov 2027 --> Oct 2025 | Active, not recruiting --> Terminated | Trial primary completion date: Nov 2027 --> Oct 2025; This trial was concluded for strategic reasons.
Trial completion date • Trial termination • Trial primary completion date
|
carboplatin • Debio 0123
2ms
Debio 0123-SCLC-104: Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based Therapy (clinicaltrials.gov)
P1, N=34, Active, not recruiting, Debiopharm International SA | Trial completion date: Jul 2026 --> Feb 2026
Trial completion date
|
carboplatin • etoposide IV • Debio 0123
3ms
Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based Therapy (clinicaltrials.gov)
P1, N=34, Active, not recruiting, Debiopharm International SA | Recruiting --> Active, not recruiting | N=78 --> 34
Enrollment closed • Enrollment change
|
carboplatin • etoposide IV • Debio 0123
3ms
A Study to Evaluate Safety and Preliminary Anti-tumor Activity of Debio 0123 as Monotherapy in Adult Participants With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=155, Active, not recruiting, Debiopharm International SA | Recruiting --> Active, not recruiting
Enrollment closed
|
Debio 0123
6ms
Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based Therapy (clinicaltrials.gov)
P1, N=78, Recruiting, Debiopharm International SA | Trial completion date: Apr 2026 --> Jul 2026
Trial completion date
|
carboplatin • etoposide IV • Debio 0123
8ms
Debio 0123-101: Study of Oral Debio 0123 in Combination With Carboplatin in Participants With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=76, Active, not recruiting, Debiopharm International SA | N=115 --> 76
Enrollment change
|
carboplatin • Debio 0123
11ms
Debio 0123-101: Study of Oral Debio 0123 in Combination With Carboplatin in Participants With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=115, Active, not recruiting, Debiopharm International SA | Recruiting --> Active, not recruiting
Enrollment closed
|
carboplatin • Debio 0123
1year
WIN-B: Clinical Study to Evaluate Debio0123 + Sacituzumab Govitecan Combination in TNBC or HR+/HER2- Advanced Breast Cancer (clinicaltrials.gov)
P1/2, N=76, Recruiting, MedSIR | Not yet recruiting --> Recruiting
Enrollment open
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 negative
|
Trodelvy (sacituzumab govitecan-hziy) • Debio 0123
1year
Debio 0123-101: Study of Oral Debio 0123 in Combination With Carboplatin in Participants With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=115, Recruiting, Debiopharm International SA | Trial completion date: Apr 2027 --> Nov 2027 | Trial primary completion date: Jun 2025 --> Nov 2027
Trial completion date • Trial primary completion date • Metastases
|
carboplatin • Debio 0123
Share via
